biote Corp. (BTMD)
| Market Cap | 357.33M |
| Revenue (ttm) | 187.32M |
| Net Income (ttm) | 8.05M |
| Shares Out | 62.04M |
| EPS (ttm) | 0.25 |
| PE Ratio | 23.00 |
| Forward PE | 16.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,736 |
| Open | 5.87 |
| Previous Close | 5.84 |
| Day's Range | 5.75 - 5.94 |
| 52-Week Range | 3.65 - 8.22 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 8.11 (+41.04%) |
| Earnings Date | May 7, 2024 |
About BTMD
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; p... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for BTMD stock is "Strong Buy." The 12-month stock price forecast is $8.11, which is an increase of 41.04% from the latest price.
News
Biote Reports First Quarter 2024 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today a...
Biote Announces Definitive Settlement with Founder
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Schedules First Quarter 2024 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
This overlooked corner of women's health could be a $350 billion market opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
Biote Reports Fourth Quarter and Full Year 2023 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today a...
Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder's Shares
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Announces $20 Million Share Repurchase Authorization
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote to Purchase Asteria Health
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Provides Preliminary 2023 Results and Initial 2024 Guidance
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Names Robert Peterson as Chief Financial Officer
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Reports Third Quarter 2023 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for...
Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial resu...
Biote Reports Second Quarter 2023 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for...
Biote Schedules Second Quarter 2023 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide second quarter financial res...
Biote Formalizes Commitment to Men's Hormone Health With Launch of New Men's Health Division
IRVING, Texas--(BUSINESS WIRE)---- $BTMD #antiaging--Biote, a leading provider of hormone optimization, has announced the launch of a dedicated Men's Health Division.
Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today an...
Biote Announces Pricing of Secondary Offering of Common Stock
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announce...
Biote to Participate at Upcoming Investor Conferences
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, toda...
Biote Appoints Mary J. Puncochar as Chief Commercial Officer
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, toda...
Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today a...
Biote Reports First Quarter 2023 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for...
Biote Schedules First Quarter 2023 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announce...
Biote Names John Denne as General Manager, Men's Health Division
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has j...
Biote Reports Fourth Quarter and Full Year 2022 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for...